Table 1 Prevalence of GATA2 overexpression in 259 patients with acute myeloid leukemia at diagnosis, and its association with cytogenetic and molecular markers

From: Overexpression of GATA2 predicts an adverse prognosis for patients with acute myeloid leukemia and it is associated with distinct molecular abnormalities

Characteristic

All cases

GATA2 not OE (n=162)

GATA2 OE (n=97)

P

Age, years

249

159

90

0.056

 Median

 

59

62.5

 

 Range

 

14–86

19–86

 

Sex

259

162

97

0.988

 Male

139

87 (62.6%)

52 (37.4%)

 

 Female

120

75 (62.5%)

45 (37.5%)

 

WBC at diagnosis, 109/l

138

87

51

0.583

 Median

 

15.0

16.6

 

 Range

 

1.1–212

0.7–220

 

BM blasts at diagnosis, %

135

86

49

0.916

 Median

 

74

70

 

 Range

 

20–100

20–99

 

Secondary AML a

256

162

94

0.054

 Yes

47

24 (51%)

23 (49%)

 

 No

209

138 (66%)

71 (34%)

 

Type of AML (FAB classification)

218

143

75

0.150

 AML-M0

20

14 (70%)

6 (30%)

 

 AML-M1

41

21 (51.2%)

20 (48.8%)

 

 AML-M2

62

42 (67.7%)

20 (32.3%)

 

 AML-M3

15

10 (66.7%)

5 (33.3%)

 

 AML-M4

32

23 (72%)

9 (28%)

 

 AML-M5

34

27 (79.4%)

7 (20.6%)

 

 AML-M6

12

5 (41.7%)

7 (58.3%)

 

 AML-M7

2

1 (50%)

1 (50%)

 

Cytogenetic prognosis group b

259

162

97

 

 Favorable

40

29

11 (27.5%)

0.638

inv(16)

11

8 (72.7%)

3 (27.3%)

 

t (8;21)

15

12 (80%)

3 (20%)

 

t (15;17)

14

9 (64.3%)

5 (35.7%)

 

 Intermediate

141

91

50 (35.4%)

0.002

Normal

105

60 (57%)

45 (43%)

 

Other aberrations

36

31 (86%)

5 (14%)

 

 Poor

78

42

36 (46.1%)

0.351

Complex

16

11 (68.8%)

5 (31.3%)

 

−5/5q- and/or −7

42

22 (52.4%)

20 (47.6%)

 

3q aberrations

20

9 (45%)

11 (55%)

 

 WT1 overexpressionc

216

137

79

<0.001

Yes

176

101 (57.4%)

75 (42.6%)

 

No

40

36 (90%)

4 (10%)

 

 EVI1 overexpressionc

188

113

75

<0.001

Yes

55

20 (36.4%)

35 (63.6%)

 

No

133

93 (70%)

40 (30%)

 
  1. Abbreviations: AML, acute myeloid leukemia; BM, bone marrow; OE, overexpression; WBC, white blood count.
  2. aSecondary AML included therapy-related AML (9 cases), and AML secondary to myelodysplastic syndrome (38 cases).
  3. bFavorable risk: t(15;17), t(8;21), inv(16)/t(16;16); unfavorable risk: inv(3) or t(3;3), t(6;9), rearrangements of 11q23 (other than t(9;11)), −5/del(5q), −7 and complex karyotype (three or more abnormalities in the absence of a World Health Organization-designated recurring chromosome abnormality); intermediate risk: normal karyotype and other chromosome abnormalities not classified as favorable or unfavorable.
  4. cVariables were dichotomized based on the calculated cutoff value.
  5. Significant results are highlighted in bold.
Back to article page